Hims & Hers Health (NYSE:HIMS) Rating Lowered to Sell at Citigroup

Citigroup lowered shares of Hims & Hers Health (NYSE:HIMS) from a neutral rating to a sell rating in a report released on Friday, Marketbeat Ratings reports. Citigroup currently has $25.00 price target on the stock, up from their previous price target of $24.00.

Other research analysts have also issued reports about the company. Morgan Stanley began coverage on Hims & Hers Health in a research report on Tuesday, December 17th. They set an “overweight” rating and a $42.00 target price on the stock. Bank of America lowered shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and decreased their price objective for the company from $32.00 to $18.00 in a research report on Thursday, November 14th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, November 6th. Canaccord Genuity Group lifted their price objective on shares of Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a research note on Monday, December 2nd. Finally, Piper Sandler upped their target price on Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a research report on Monday, January 6th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Hold” and an average price target of $25.13.

Hims & Hers Health Stock Down 1.2 %

Shares of NYSE HIMS opened at $25.41 on Friday. Hims & Hers Health has a twelve month low of $8.14 and a twelve month high of $35.02. The firm has a market cap of $5.55 billion, a PE ratio of 57.75 and a beta of 1.31. The business has a fifty day simple moving average of $27.21 and a two-hundred day simple moving average of $21.64.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. The company had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Hims & Hers Health’s revenue for the quarter was up 77.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.04) earnings per share. On average, research analysts expect that Hims & Hers Health will post 0.29 earnings per share for the current year.

Insider Activity

In other news, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $20.88, for a total transaction of $3,943,981.44. Following the transaction, the chief executive officer now owns 67,015 shares in the company, valued at $1,399,273.20. The trade was a 73.81 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Soleil Boughton sold 2,339 shares of the business’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $20.41, for a total transaction of $47,738.99. Following the transaction, the insider now directly owns 172,274 shares in the company, valued at approximately $3,516,112.34. The trade was a 1.34 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,063,707 shares of company stock worth $28,696,798 over the last 90 days. 17.71% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC lifted its position in shares of Hims & Hers Health by 113.1% during the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock worth $121,936,000 after purchasing an additional 3,205,108 shares in the last quarter. State Street Corp boosted its position in Hims & Hers Health by 4.7% in the 3rd quarter. State Street Corp now owns 4,626,543 shares of the company’s stock valued at $85,221,000 after buying an additional 206,078 shares during the period. Geode Capital Management LLC increased its position in shares of Hims & Hers Health by 12.7% during the third quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock worth $79,029,000 after acquiring an additional 482,177 shares during the period. Wellington Management Group LLP raised its stake in shares of Hims & Hers Health by 34.5% in the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock valued at $63,446,000 after acquiring an additional 883,230 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Hims & Hers Health by 15.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company’s stock valued at $30,714,000 after purchasing an additional 218,566 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.